Proactive Investors - Run By Investors For Investors

RhoVac AB looks to begin Phase 2b trials with prostate cancer drug in 2Q 2019

RhoVac AB (OMX:RHOVAC) CEO Anders Ljungqvist sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Sweden and Denmark-based immuno-oncology company is developing a therapeutic cancer vaccine that targets metastatic cancer cells.  The company's cancer vaccine product RV001, in clinical trial, recognizes metastatic cancer cells and stimulates the immune system to target them.

View full RHOVA profile View Profile

RhoVac AB Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use